NCT07544953 · NOT YET RECRUITING
Amyloid Monoclonal Antibody Treatment in PD Patients With Coexistent AD Pathology
This study looks at whether lecanemab, an anti-amyloid antibody already approved for early Alzheimer's, can lower amyloid plaque on brain scans over 18 months in people with Parkinson's disease who also have amyloid buildup and memory or thinking problems. It is compared with a group not receiving the drug. No phase is listed.
You may qualify if
- Patients diagnosed with Parkinson's disease
- Amyloid deposition confirmed by FBB PET
- Mild cognitive impairment or early dementia (CDR 0.5 or 1) on neuropsychological tests
- Adults aged 50-90 years
You're excluded if
- Cases in which lecanemab administration is contraindicated (based on recommendations from the Korean Dementia Association)
- Cases in which neuropathologies other than Parkinson's disease or Alzheimer's disease are suspected as the underlying disease
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-04-22